Is Cagrilintide FDA approved?
No. This profile records Cagrilintide as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
THE SATIETY SIGNAL
Acylated amylin analog
Cagrilintide is an amylin-mimicking peptide that strongly suppresses appetite and slows gastric emptying, working alongside GLP-1s to boost satiety and support sustained weight loss.
Not FDA approved · research use only
Reviewed by our clinical team
1 research sources
Sep 1, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
No. This profile records Cagrilintide as not FDA approved and for research use only.
Review the regulatory and source details on this page for the current context.
Dose: 2.4 mg once weekly (subcutaneous).
Schedule: weekly. Cycle: 8+ weeks (ongoing treatment). This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 1 curated or current research sources.
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Activates satiety centers in the brain to reduce hunger
Delays stomach emptying so you feel full longer
Suppresses glucagon and improves insulin sensitivity
The live research feed did not return papers for this page. The curated references below remain available for crawlable source context.